Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation
A 14-day course of prophylactic GLE/PIB is safe and effective for HCV positive-to-negative kidney transplants and may prevent HCV transmission or significantly reduce the VL for those with detectable transmission, allowing rapid clearance within 2 weeks.
Authors
- Elaina Weldon
- Jonathan Berger (ORCID: https://orcid.org/0000-0002-9085-0900)
- Ian Jaffe (ORCID: https://orcid.org/0000-0002-7309-308X)
- Rebecca Dieter (ORCID: https://orcid.org/0000-0001-7906-1372)
- Robert A. Montgomery (ORCID: https://orcid.org/0000-0001-9914-6082)
- Aprajita Mattoo
- Nicole Ali (ORCID: https://orcid.org/0000-0003-1209-2873)
- Bonnie E. Lonze (ORCID: https://orcid.org/0000-0002-0973-1657)
- Perry Hotchkis
Institutions
- NYU Langone Health (US)
- Miami Transplant Institute (US)
- New York University (US)
- University of La Verne (US)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/ndt/gfae271
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- AbbVie
- National Institutes of Health
- National Center for Advancing Translational Sciences